RBM3

Across TCGA pan-cancer cohorts, RBM3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RBM3 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where RBM3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	III,IV	0.528	0.817	<.001	51	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
LSCC	OS	Quartile	All	0.707	0.953	.019	6	view →
LUAD	DFS	Quartile	III,IV	0.203	0.666	.012	6	view →
UCEC	OS	Median	III,IV	0.492	0.884	.031	4	view →
CCRCC	OS	Median	III,IV	1.000	0.353	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RBM3–HNSC (OS)

Open the HNSC breakdown →